Man's torso showing circulatory system

Moving Cardiovascular Product Innovations from Lab to Market

The current average time for regulatory approval and reimbursement of a new cardiovascular therapy is 12.5 years at a cost of $2.5 billion. A new course from the University of Arizona College of Medicine-Phoenix and the University of Arizona office of Continuing and Professional Education may change that.

The four-course Cardiovascular Translational Science & Medicine program will teach participants how to expedite moving potentially therapeutic cardiovascular products from idea to clinical application through the regulatory process.

The program was created by Dr. Nabil Dib, MD, founder of the International Society for Cardiovascular Translation Research (ISCTR) and Robert Roberts, MD, who holds the ISCTR chair at the UA College of Medicine – Phoenix. They are both renowned researchers who have made groundbreaking contributions in cardiology.

From the Lab to the Market in Record Time

The Cardiovascular Translational Science & Medicine program is the only course in the world designed to help participants move their research from lab to market through the regulatory process.

As Dr. Robert Roberts describes it:

"This is a very, very unique course and a very unique initiative that no one has ever tried to do before...what is exciting about this course? No question. You have an opportunity here to truly influence patient care and improve it."

Dr. Dib concurs:

“This is a new approach to science that expedites the therapy to patients and decreases the cost. These are critical steps that have never been taught in medical school.”

The University of Arizona Cardiovascular Translational Science & Medicine Program

Program participants will learn about all aspects of effectively developing, testing, and marketing their research. The courses include lectures from 48 renowned international experts from the cardiology field, academia, the cardiovascular therapeutic products industry and regulatory agencies. The curriculum is fully online, so participants can learn at their convenience. 

The Cardiovascular Translational Science & Medicine program is composed of four courses:

  • Introduction
  • Devices
  • Drugs
  • Biologics

The Introduction to Cardiovascular Translational Science & Medicine course provides an introduction to biology, genetics, product management, intellectual property, funding and other critical topics in cardiovascular therapeutic product development and innovation.

After the introductory course, participants can choose which of these pathways to explore based on their interests and responsibilities. Digital badges will be awarded upon completion of each course for recognition of participants' accomplishments.

The newly-launched Cardiovascular Translational Science & Medicine: Devices course is designed to enhance implementation of translation pathways to expedite potential cardiovascular therapeutic devices from conceptualization to clinical application. 

This program is a collaboration between the UA College of Medicine – Phoenix and the International Society for Cardiovascular Translational Research (ISCTR).

Learn More

To learn more, contact

  • Patricia Cook, University of Arizona Continuing and Professional Education, at (520) 626-3343 or via email at 
  • Kathy Gonzales, University of Arizona College of Medicine Phoenix, at (602) 827-2677 or via email at